Literature DB >> 15555052

Culture confluence regulates gene expression of normal human keratinocytes.

Jeng-Yu Lai1, Mark R Pittelkow.   

Abstract

Keratinocytes are frequently used to examine efficacy of wound healing products and dermatological agents in vitro. Cultured keratinocyte sheets are also used as autologous or allogenic grafts to promote wound closure. Because it is well known that the expression patterns of keratin genes change when cell cultures reach confluence, we investigated the expression pattern of wound healing-related genes, including growth factors and cytokines. Of additional particular interest is a novel wound healing related factor, secretory leukocyte protease inhibitor (SLPI), which appears to enhance tissue repair. We found that the expression pattern varied for specific genes expressed by keratinocytes as confluence was reached. Specifically, SLPI expression peaked in the early postconfluent state and vascular endothelial growth factor and amphiregulin in the late postconfluent state. Some gene products exhibit autocrine activity, whereas others exert paracrine regulation of growth. These findings indicate that it is critical to define the growth and differentiation state of human keratinocyte cultures to better determine responses and efficacy in vitro to various dermatological/wound care agents tested.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15555052     DOI: 10.1111/j.1067-1927.2004.12606.x

Source DB:  PubMed          Journal:  Wound Repair Regen        ISSN: 1067-1927            Impact factor:   3.617


  2 in total

1.  Cell culture models demonstrate that CFTR dysfunction leads to defective fatty acid composition and metabolism.

Authors:  Charlotte Andersson; M Rabie Al-Turkmani; Juanito E Savaille; Ragheed Alturkmani; Waddah Katrangi; Joanne E Cluette-Brown; Munir M Zaman; Michael Laposata; Steven D Freedman
Journal:  J Lipid Res       Date:  2008-04-25       Impact factor: 5.922

2.  Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery.

Authors:  Sabine Schuster; Beáta Biri-Kovács; Bálint Szeder; Viktor Farkas; László Buday; Zsuzsanna Szabó; Gábor Halmos; Gábor Mező
Journal:  Beilstein J Org Chem       Date:  2018-04-04       Impact factor: 2.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.